Trispecific CAR T Cells Demonstrate Safety, Early Activity in B-Cell Lymphoma - CancerNetwork

“Advanced-stage high-grade B-cell lymphoma (MYC-R with BCL2 and/or BCL6-R), single-centre series, n=124: 69 MYC/BCL2, 34 triple hit, 21 MYC/BCL6. Targeted NGS in 36. CR 44%, 2-year OS 59.8%, CNS relapse 10.1%.

AJMC news storyOncologic factors, not HIV viral suppression status, determine how well people with HIV fare after a lymphoma diagnosis, according to a retrospective cohort study published in HIV Medicine. Lymphoma has remained one of the most common cancers in people with HIV since the earliest years of the epidemic, and that risk has persisted even as antiretroviral therapy (ART) transformed HIV from a fatal illness into a manageable chronic condition. A 2024 protocol published in BMJ Open, outlining a planned systematic review to quantify that excess burden worldwide, noted that people with AIDS face roughly 400 times the risk of high-grade non-Hodgkin lymphoma (NHL) and about 15 times the risk of low-grade NHL compared with the general population. Because ART has sharply reduced AIDS-defining malignancies, clinicians have debated whether virologic control should factor into how aggressively to treat a lymphoma, or whether oncologic staging and histology alone should drive therapy.

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 20% to 25% of NHL diagnoses in Canada. Approximately 2,400 to 3,000 Canadians are diagnosed with FL each year. Follicular lymphoma is difficult to treat and often returns.1,2 Although treatment can control the disease, follicular lymphoma is generally considered incurable, with patients typically experiencing repeated relapses and progressively shorter remissions over time.3

Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study, published in JAMA Network Open, was led by Bryan Valcarcel, MD, Instructor, and Luis Malpica Castillo, MD, Associate Professor, both of the Department of Lymphoma & Myeloma at MD Anderson. The researchers analyzed data from 2000 to 2017, including more than 20,000 survivors of Hodgkin lymphoma with an average age of 36 years. Eligible patients were 20 years and older at the time of their initial diagnosis of Hodgkin lymphoma. They reported 2,899 deaths occurred among survivors, whereas in the general population 1,481 deaths would have been expected. While the majority of deaths were related to cancer, noncancer adverse health conditions also were increased in the survivors of Hodgkin lymphoma.